Completed

Assessing 72-Hour Efficacy of Tripled Daily Buprenorphine Maintenance Dose

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Narcotic-Related Disorders+2

+ Mental Disorders

+ Opioid-Related Disorders

From 20 to 49 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: June 1993
See protocol details

Summary

Principal SponsorNational Institute on Drug Abuse (NIDA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 1993

Actual date on which the first participant was enrolled.

This study aims to explore the effects of alternate-day administration of Buprenorphine, a medication used for opioid dependence. The goal is to understand if a dose three times the daily maintenance amount can last for 72 hours without any changes in its effects. The study focuses on individuals who require opioid dependence treatment, seeking to address the challenge of maintaining consistent effects with less frequent dosing. The potential outcomes of this research could lead to improved treatment strategies for opioid dependence, making treatment more manageable for those affected.

Official TitleAlternate-Day Buprenorphine Administration. Phase IV
NCT00000223
Principal SponsorNational Institute on Drug Abuse (NIDA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 20 to 49 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Narcotic-Related DisordersMental DisordersOpioid-Related DisordersSubstance-Related DisordersChemically-Induced Disorders

Criteria

Please contact site for information.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Treatment Research Center

Burlington, United StatesOpen Treatment Research Center in Google Maps
CompletedOne Study Center
Assessing 72-Hour Efficacy of Tripled Daily Buprenorphine Maintenance Dose | PatLynk